Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2017Journal of Hematology & OncologyOpen Access

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKurt SchönfeldBiotest (Germany)CZChantal ZuberJPJan PinkasAVEO Oncology (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Schönfeld et al. (2017) studied this question.

synapsesocial.com/papers/6aa0195a20bdbf3a879c9de4https://doi.org/10.1186/s13045-016-0380-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1European Perspective on Multiple Myeloma Treatment Strategies in 20142014 · 100 citations
  2. 2Future agents and treatment directions in multiple myeloma2013 · 31 citations
  3. 3B lymphocytes express and lose syndecan at specific stages of differentiation.1989 · 413 citations
  4. 4BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity2012 · 62 citations
  5. 5Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib2014 · 44 citations